{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:51:14Z","timestamp":1790412674691,"version":"4.1.0"},"reference-count":36,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,1,9]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Describe characteristics, treatment patterns and clinical outcomes of patients with small-cell lung cancer (SCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective chart review study defining several cohorts: (1) limited-stage disease (LD) SCLC initiating 1L therapy (1\u2009L LD-SCLC), (2) extensive-stage disease (ED) SCLC initiating 1L therapy (1L ED-SCLC) and (3) patients initiating 2L therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>39 physicians (medical oncologists, thoracic oncologists and\/or pulmonologists) from France, Italy and the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients &gt;18 years of age with a confirmed diagnosis of LD-SCLC or ED-SCLC and a full oncology medical history. Patients included initiated a 1L (2013\u20132015) or 2L (2013\u20132016) treatment (chemotherapy and\/or radiotherapy\u2014RT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>231 patients in 1L LD-SCLC, 308 in 1L ED-SCLC and 225 with relapse\/refractory SCLC initiating 2L treatment were included. The proportion of men was higher across all groups (56.8% to 68.5%) and mean age at time of diagnosis was 66.0 and 65.4 years in 1L LD-SCLC and 2L ED-SCLC cohorts. The majority of patients in LD-SCLC 1L group received chemotherapy with RT (76.2%). Patients initiating 2L therapy predominantly received chemotherapy alone (79.6%).<\/jats:p>\n                    <jats:p>Median OS in 1\u2009L patients was 17.3 months in LD-SCLC and 8.8 months in ED-SCLC. Median PFS was 11.6 months in LD-SCLC and 6.1 months in ED-SCLC patients. Median OS in patients initiating 2L treatment was 6.6 months. OS from start of 2L treatment was lower in patients initially diagnosed with ED (5.1 months) than in patients initially diagnosed with LD (9.3 months) (p&lt;0.0001). OS and PFS were assessed from the start of 1L or 2L therapy, depending on the cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the availability of a high number of treatments and combinations, the prognosis of SCLC is still unsatisfactory, especially for those patients diagnosed with ED-SCLC, indicating high unmet need in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-052556","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T11:12:14Z","timestamp":1675681934000},"page":"e052556","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study"],"prefix":"10.1136","volume":"13","author":[{"given":"Fiona","family":"Blackhall","sequence":"first","affiliation":[{"name":"Lung Disease Cancer, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Curie-Montsouris Thorax Institute, Institut Curie, Paris, \u00cele-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Livartowski","sequence":"additional","affiliation":[{"name":"Curie-Montsouris Thorax Institute, Institut Curie, Paris, \u00cele-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7087-6548","authenticated-orcid":false,"given":"Laura","family":"McDonald","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-9814","authenticated-orcid":false,"given":"Montserrat","family":"Roset","sequence":"additional","affiliation":[{"name":"Real World Insights, IQVIA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lara","sequence":"additional","affiliation":[{"name":"Real World Insights, IQVIA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Juarez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"2025121422290541000_13.2.e052556.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87"},{"key":"2025121422290541000_13.2.e052556.2","unstructured":"Globocan. 2018. Available: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/724-spain-fact-sheets.pdf"},{"key":"2025121422290541000_13.2.e052556.3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-319-40389-2_14","article-title":"Small cell lung cancer","volume":"170","author":"Bernhardt","year":"2016","journal-title":"Cancer Treat Res"},{"key":"2025121422290541000_13.2.e052556.4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.11.009","article-title":"Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy","volume":"127","author":"Coutinho","year":"2019","journal-title":"Lung Cancer"},{"key":"2025121422290541000_13.2.e052556.5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cllc.2019.06.006","article-title":"Impact of lung cancer treatment on cognitive functioning","volume":"21","author":"van de Kamp","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2025121422290541000_13.2.e052556.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"2025121422290541000_13.2.e052556.7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cllc.2016.05.014","article-title":"SCLC-state of the art and what does the future have in store?","volume":"17","author":"Kahnert","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"2025121422290541000_13.2.e052556.8","first-page":"26","article-title":"Treatment for small cell lung cancer, where are we now? -A review","volume":"5","author":"Alvarado-Luna","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"2025121422290541000_13.2.e052556.9","doi-asserted-by":"publisher","DOI":"10.21037\/qims.2018.08.02"},{"key":"2025121422290541000_13.2.e052556.10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2147\/OTT.S44201","article-title":"New dilemmas in small-cell lung cancer TNM clinical staging","volume":"6","author":"Zarogoulidis","year":"2013","journal-title":"Onco Targets Ther"},{"key":"2025121422290541000_13.2.e052556.11","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.01.16"},{"key":"2025121422290541000_13.2.e052556.12","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.009068"},{"key":"2025121422290541000_13.2.e052556.13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2010.06.003","article-title":"Characteristics, treatment patterns and outcomes of patients with small cell lung cancer -- a retrospective single institution analysis","volume":"71","author":"Hermes","year":"2011","journal-title":"Lung Cancer"},{"key":"2025121422290541000_13.2.e052556.14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29098"},{"key":"2025121422290541000_13.2.e052556.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"2025121422290541000_13.2.e052556.16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JOP.18.00204","article-title":"Managing patients with relapsed small-cell lung cancer","volume":"14","author":"Gong","year":"2018","journal-title":"J Oncol Pract"},{"key":"2025121422290541000_13.2.e052556.17","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-Cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24 Suppl 6","author":"Fr\u00fch","year":"2013","journal-title":"Ann Oncol"},{"key":"2025121422290541000_13.2.e052556.18","first-page":"4189","article-title":"Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation","volume":"46","author":"Osterlind","year":"1986","journal-title":"Cancer Res"},{"key":"2025121422290541000_13.2.e052556.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.06.002"},{"key":"2025121422290541000_13.2.e052556.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025121422290541000_13.2.e052556.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2025121422290541000_13.2.e052556.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"2025121422290541000_13.2.e052556.23","unstructured":"FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer. 2018. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-nivolumab-accelerated-approval-third-line-treatment-metastatic-small-cell-lung-cancer"},{"key":"2025121422290541000_13.2.e052556.24","unstructured":"US Food and Drug Administration . FDA approves pembrolizumab for metastatic small cell lung cancer. 2019. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-metastatic-small-cell-lung-cancer"},{"key":"2025121422290541000_13.2.e052556.25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1795995","article-title":"Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer","volume":"9","author":"Kepp","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025121422290541000_13.2.e052556.26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cllc.2018.12.019","article-title":"Advancements in small-cell lung cancer: the changing landscape following impower-133","volume":"20","author":"Pacheco","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2025121422290541000_13.2.e052556.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"2025121422290541000_13.2.e052556.28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17476348.2020.1681977","article-title":"Nivolumab for the treatment of small cell lung cancer","volume":"14","author":"Simeone","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"2025121422290541000_13.2.e052556.29","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4504","article-title":"Barriers to combined-modality therapy for limited-stage small cell lung cancer","volume":"4","author":"Pezzi","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121422290541000_13.2.e052556.30","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.3747\/co.26.4481","article-title":"Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review","volume":"26","author":"Sun","year":"2019","journal-title":"Curr Oncol"},{"key":"2025121422290541000_13.2.e052556.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156494","article-title":"Increased biological effective dose of radiation correlates with prolonged survival of patients with limited-stage small cell lung cancer: A systematic review","volume":"11","author":"Zhu","year":"2016","journal-title":"PLoS One"},{"key":"2025121422290541000_13.2.e052556.32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.7150\/jca.13080","article-title":"Second-Line therapy of small-cell lung cancer: topotecan compared to a combination treatment with adriamycin, cyclophosphamide and vincristine (ACO)-a single center experience","volume":"6","author":"Hagmann","year":"2015","journal-title":"J Cancer"},{"key":"2025121422290541000_13.2.e052556.33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000486038","article-title":"Efficacy of platinum-based chemotherapy for relapsed small-cell lung cancer after amrubicin monotherapy in elderly patients and patients with poor performance status","volume":"94","author":"Igawa","year":"2018","journal-title":"Oncology"},{"key":"2025121422290541000_13.2.e052556.34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-017-3403-9","article-title":"A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients","volume":"80","author":"Imai","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025121422290541000_13.2.e052556.35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014758","article-title":"Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed\/refractory small cell lung cancer: retrospective single-institution observational study","volume":"98","author":"Sugiyama","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025121422290541000_13.2.e052556.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01074"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-052556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:29:16Z","timestamp":1765780156000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-052556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,6]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjopen-2021-052556"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-052556","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}